Publications by authors named "L E Chambless"
Background: Meningiomas exhibit considerable clinical and biological heterogeneity. We previously identified four distinct molecular groups (immunogenic, NF2-wildtype, hypermetabolic, proliferative) that address much of this heterogeneity. Despite the utility of these groups, the stochasticity of clustering methods and the use of multi-omics data for discovery limits the potential for classifying prospective cases.
View Article and Find Full Text PDFArticle Synopsis
- - The study validates a new DNA methylation-based predictor for meningiomas that has been enhanced for use with modern methylation arrays and shows improved accuracy over the standard 2021 WHO grading system.
- - It uses data from 1,347 meningioma cases, including prospective cases and an external cohort, demonstrating that both the new and original models effectively predict early postoperative recurrence, especially within specific risk subgroups.
- - The new predictor, which is simpler with fewer features, allows for better clinical decision-making, including the use of adjuvant radiotherapy for high-risk patients, and is available as an easy-to-use tool for improved patient stratification in clinical trials.
Cost of Vestibular Schwannoma Treatment: A Systematic Review and Meta-Analysis.
J Neurol Surg B Skull Base
December 2024
Research furthering treatment efficacy for microsurgical resection and stereotactic radiosurgery for vestibular schwannoma (VS) is ever-growing; however, there remains a paucity of research addressing treatment costs. Our aim is to define the reported costs of different treatment modalities used for VS. A systematic review of the literature for VS treatment cost was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines using PubMed and Web of Science databases.
View Article and Find Full Text PDFArticle Synopsis
- * This systematic review followed PRISMA guidelines to analyze 21 studies out of 249 citations screened, highlighting radiomics' potential to differentiate medulloblastomas from other tumors and identify their subtypes.
- * The findings suggest that while radiomics shows promise for predicting survival rates in medulloblastoma patients, further research is needed to fully assess its clinical value.
Article Synopsis
- Treatment for meningiomas primarily involves surgery and sometimes radiation, but patient responses can vary significantly.
- Researchers analyzed data from 2,824 meningiomas, including both retrospective and prospective information, to identify molecular biomarkers that predict treatment response.
- The study found that complete tumor removal and proper treatment of the dural margin significantly improve survival rates, and developed a new molecular model that better predicts how patients will respond to radiotherapy compared to traditional classification methods.